BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1264@pharmaconomics
DTSTAMP:20260707T040437Z
DTSTART;VALUE=DATE:20260420
DTEND;VALUE=DATE:20260421
SUMMARY:NVO Phase 3 — etavopivat
DESCRIPTION:Phase 3 trial results for etavopivat in sickle cell disease are due Apr 20\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/353278/000117184326002549/f6k_042026.htm\n\nTrack it: https://www.pharmaconomics.com/e/1264
URL:https://www.pharmaconomics.com/e/1264
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:NVO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR